



## Article

# Robust Copper Metal–Organic Framework-Embedded Polysiloxanes for Biomedical Applications: Its Antibacterial Effects on MRSA and In Vitro Cytotoxicity

Kihak Gwon <sup>1</sup>, Youngmee Kim <sup>2</sup>, Hyunjun Cho <sup>3</sup>, Seonhwa Lee <sup>1</sup>, So-Hyeon Yang <sup>2</sup>, Sung-Jin Kim <sup>2</sup> and Do Nam Lee <sup>1,\*</sup>

<sup>1</sup> Ingenium College of Liberal Arts (Chemistry), Kwangwoon University, Seoul 01897, Korea; khgwon@kw.ac.kr (K.G.); seonhwalee@kw.ac.kr (S.L.)

<sup>2</sup> Department of Chemistry and Nano Science, Institute of Nano-Bio Technology, Ewha Womans University, Seoul 03760, Korea; ymeekim@ewha.ac.kr (Y.K.); auung22@ewhain.net (S.-H.Y.); sjkim@ewha.ac.kr (S.-J.K.)

<sup>3</sup> Department of Chemistry, Dongguk University, Seoul 04620, Korea; vchol1212@dgu.ac.kr

\* Correspondence: donamlee2@kw.ac.kr; Tel.: +82-2-940-5658

**Abstract:** Polysiloxanes (PSs) have been widely utilized in the industry as lubricants, varnishes, paints, release agents, adhesives, and insulators. In addition, their applications have been expanded to include the development of new biomedical materials. To modify PS for application in therapeutic purposes, a flexible antibacterial Cu-MOF (metal–organic framework) consisting of glutarate and 1,2-bis(4-pyridyl)ethane ligands was embedded in PS via a hydrosilylation reaction of vinyl-terminated and H-terminated PSs at 25 °C. The bactericidal activities of the resulting Cu-MOF-embedded PS (PS@Cu-MOF) and the control polymer (PS) were tested against *Escherichia coli*, *Staphylococcus aureus*, and methicillin-resistant *Staphylococcus aureus*. PS@Cu-MOF exhibited more than 80% bactericidal activity toward the tested bacteria at a concentration of 100 µg·mL<sup>-1</sup> and exhibited a negligible cytotoxicity toward mouse embryonic fibroblasts at the same concentration. Release tests of the Cu(II) ion showed PS@Cu-MOF to be particularly stable in a phosphate-buffered saline solution. Furthermore, its physical and thermal properties, including the phase transition, rheological measurements, swelling ratio, and thermogravimetric profile loss, were similar to those of the control polymer. Moreover, the low cytotoxicity and bactericidal activities of PS@Cu-MOF render it a promising candidate for use in medicinal applications, such as in implants, skin-disease treatment, wound healing, and drug delivery.

**Keywords:** Cu-MOF; polysiloxane (PS); hydrosilylation; antibacterial agent; cytocompatibility; biomedical application



**Citation:** Gwon, K.; Kim, Y.; Cho, H.; Lee, S.; Yang, S.-H.; Kim, S.-J.; Lee, D.N. Robust Copper Metal–Organic Framework-Embedded Polysiloxanes for Biomedical Applications: Its Antibacterial Effects on MRSA and In Vitro Cytotoxicity. *Nanomaterials* **2021**, *11*, 719. <https://doi.org/10.3390/nano11030719>

Academic Editor: Fernando Novio

Received: 14 February 2021

Accepted: 8 March 2021

Published: 12 March 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The use of antimicrobial plastics has attracted considerable attention in medicinal and biomedical engineering fields in recent years. Medical polymers must be harmless to the living body, wherein they should exhibit a high biocompatibility with tissues, cells, and blood to avoid immune rejection reactions, and they must maintain their necessary physical and mechanical properties within the host [1–9]. Polysiloxane (PS) materials exhibit interesting properties including good thermal and oxidative stabilities, dielectric insulating properties, fouling release properties, and excellent biocompatibilities [10,11]. As a result, PSs have been widely utilized in the industry as lubricants, varnishes, paints, release agents, adhesives, and insulators [12–18]. In addition, due to their physicochemical properties, the uses of PS have been expanded to include medical materials such as tubes, pre-coating needles, syringes, artificial heart valves, pacemakers, and contact lenses [19–21]. Many studies have therefore been conducted to develop a surface modification method to impart antibacterial properties to PS for its use in biological applications. In fact, many

literature reports have indicated that surface-modified PSs exhibit a good antibacterial effect when coated with silver nanoparticles, organic antibiotics, quaternary ammonium salts, chitosan, and antimicrobial drugs or other materials [22–33].

Recently, metal–organic frameworks (MOFs), which are porous coordination materials composed of organic ligands and metal ions, have received considerable interest as antibacterial materials for biological, environmental, and food applications, owing to their sustained release capability, porosity, structural flexibility, and antibacterial properties [34–38]. However, the release of excess metal ions from MOFs can have toxic effects on the host tissues, as well as microbes, and so it is desirable to improve their stabilities [39–41]. Considerable efforts have therefore been expended to improve the antibacterial durabilities of such materials and to reduce any adverse effects. This has been achieved by covalently introducing biocidal functions to the polymer [42,43]. Recently, our group developed a series of stable antibacterial MOFs (i.e., Cu-, Co-, and Zn-based MOFs), which were embedded into photo cross-linkable hydrogels for drug delivery. Importantly, the Cu-MOF-embedded hydrogels exhibited an excellent bactericidal activity against both *Escherichia coli* and *Staphylococcus aureus*, with no observed cytotoxicity [44]. Notably, we reported that Cu-MOFs containing glutarate (Glu) and bis(4-pyridyl) ligands showed very excellent bioactivity toward various bacteria [45].

Thus, we herein report the development of a simple antibacterial Cu-MOF-embedded PS scaffold with negligible toxicity, which is prepared via a hydrosilylation method. More specifically, an antibacterial Cu-MOF containing Glu and 1,2-bis(4-pyridyl)ethane (bpa) is prepared, using a previously reported method, and embedded on PS via hydrosilylation reactions with vinyl-terminated PS (PS-vinyl) and hydrogen-terminated PS (PS-H) at 25 °C. Their characterizations were investigated using powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier-transform infrared spectroscopy (FT-IR), rheological measurements, scanning electron microscopy–energy dispersive X-ray spectroscopy (SEM-EDS), and inductively coupled plasma mass spectrometry (ICP-MS). Overall, this study focuses on the development of a new type of antibacterial PS, which can be widely applied in drug delivery, wound healing, and antibacterial coatings for medical devices and implants, as determined by the evaluation of the antibacterial activity against *Escherichia coli* (*E. coli*), *Staphylococcus aureus* (*S. aureus*), and methicillin-resistant *Staphylococcus aureus* (MRSA). The in vitro cytotoxicity of PS and PS@Cu-MOF against mouse embryonic fibroblasts is also examined and discussed.

## 2. Materials and Methods

### 2.1. Preparation of the Cu-MOF

The Cu-MOF, consisting of glutarate (Glu) and bpa ligands, was synthesized hydrothermally via a previously reported method, and its formula was determined to be  $(\text{Cu}_2(\text{Glu})_2(\text{bpa})) \cdot 3\text{H}_2\text{O}$  [45,46]. More specifically, a mixture of  $\text{Cu}(\text{NO}_3)_2 \cdot 3\text{H}_2\text{O}$  (2.0 mmol, 99%, Sigma-Aldrich, St. Louis, MO, USA), glutaric acid (2.0 mmol, 99%, Sigma-Aldrich, St. Louis, MO, USA), and bpa (1.0 mmol, 99%, Sigma-Aldrich, St. Louis, MO, USA) was prepared in distilled water containing 1.0 M NaOH, and the hydrothermal reaction was carried out at 80 °C as reported. The obtained Cu-MOF was analyzed by PXRD and FT-IR.

### 2.2. Preparation of PS and the Cu-MOF-Embedded PS (PS@Cu-MOF)

The Cu-MOF-embedded PS (PS@Cu-MOF) was prepared through a hydrosilylation reaction between two PS components with a  $\text{TiO}_2$  additive in the presence of a Pt catalyst (KE-1300 and CAT-1300, Shin-Etsu Chem. Co., Tokyo, Japan) and Cu-MOF. More specifically, the vinyl-terminated PS (PS-vinyl) containing the Pt catalyst and  $\text{TiO}_2$  additive was mixed thoroughly with the Cu-MOF ( $100 \mu\text{g} \cdot \text{mL}^{-1}$ ) for 10 min, and then the hydrogen-terminated PS (PS-H) was added to the mixture (10:1 weight ratio of vinyl/hydrogen) and thoroughly mixed for an additional 5 min. Subsequently, the mixture was degassed under vacuum and pipetted into a  $50 \times 50 \text{ mm}^2$  glass mold prior to vulcanizing for 24 h at 25 °C. PS alone (i.e., without the Cu-MOF) was also prepared in the same manner and employed

as a positive control. The obtained polymers were characterized by PXRD, DSC, TGA, SEM-EDS, Rheometer, and ICP-MS.

### 2.3. Instrumentation

PXRD patterns of Cu-MOF, PS, and PS@Cu-MOF were recorded using a Rigaku Mini-Flex diffractometer (Rigaku Corp, Neu-Isenburg, Germany). The FT-IR spectrum was measured on a Bio-Rad FTS 135 spectrometer (Hercules, CA, USA). DSC runs were carried out using a DSC 214 Polyma (NETZSCH, Burlington, MA, USA). TGA was performed using a TG 209 F3 Tarsus<sup>®</sup> instrument (NETZSCH, Burlington, MA, USA). The surface morphology and elemental composition of PS and the PS@Cu-MOF scaffolds were characterized using SEM-EDS (FE-SEM, JEOL JSM-5800F, Peabody, MA, USA). The mechanical properties of PS and PS@Cu-MOF were evaluated using a TA rheometer (Discovery HR 10, New Castle, DE, USA). The degradation of PS@Cu-MOF was carried out by ICP-MS (Agilent Marker 7700, RF Generator Power 1550 W, Tokyo, Japan). The colorimetric absorbance was determined using a microplate reader (Synergy H1, BioTek, Winooski, VT, USA), and the live/dead double-stained cells were imaged by fluorescence microscopy (IX83, Olympus, Center Valley, PA, USA).

### 2.4. Mechanical Properties of the PS@Cu-MOF

For the rheological measurements, PS@Cu-MOF and PS (8 mm in diameter, 1 mm thickness) were prepared and soaked in 0.01 M pH 7.4 PBS for 2 d at 37 °C. The frequency sweep test (from 0.01 to 100 rad/s) was tested at 1% strain and 25 °C. To quantify the swelling ratios of PS and PS@Cu-MOF, both samples were allowed to reach their fully swollen states and then weighed ( $W_s$ ) after drying the outer surface carefully with a tissue. Each sample was then lyophilized for two days and weighed ( $W_d$ ), and the swelling ratios were calculated as follows:

$$\text{Swelling ratio} = \frac{W_s}{W_d} \quad (1)$$

### 2.5. Degradation and Metal Ion Release Tests

To assess whether PS@Cu-MOF could release its constituent metal ions, each of the four solutions containing PS@Cu-MOF was prepared at concentration of 1 mg·mL<sup>-1</sup> in 0.9% phosphate-buffered saline (PBS) and stirred at 25 °C for 6, 12, 24, or 48 h. Subsequently, each sample was subjected to centrifugation, and the supernatant was separated from the reaction tube. The quantity of Cu(II) ions released was measured by ICP-MS analysis of the supernatant. The degree of degradation was expressed as the concentration of Cu(II) ions released into the PBS, in µg·mL<sup>-1</sup>, at each release test time.

### 2.6. Antibacterial Tests

Antibacterial activity tests on PS and PS@Cu-MOF were carried out using the following three strains of bacteria: *E. coli* (ATCC 8739), *S. aureus* (ATCC 6538P), and MRSA (ATCC 33591), according to a previously reported colony counting method [44]. More specifically, to measure the antibacterial activity of PS@Cu-MOF against the three bacterial strains, three specimens of PS@Cu-MOF and a stomacher film for the blank (5 × 5 ± 0.2 cm, within 1 cm thickness) were prepared and tested according to the following method. As a positive control, PS (without the MOF) was also prepared and evaluated. The sample was completely dried after wiping three times with an ethanol-soaked gauze. The pre-cultured test bacteria with a concentration of ~10<sup>5</sup> cfu · mL<sup>-1</sup> (colony-forming units) were routinely inoculated. Each test sample was placed in a Petri dish with the test side up. Subsequently, an aliquot (200 µL) of the test solution was inoculated onto each test piece. The film placed on the dropped test bacterium was lightly pressed to cover it with the test bacterium. The test sample, and the control inoculated with the test strain, were incubated for 24 h at 37 °C. After inoculation, the uncoated test pieces bearing the test strain were immediately separated using sterilized tweezers, and SCDLP medium (10 mL) was added to wash off the test bacteria. The viable cell count of this washing solution was measured. Subsequently,

1 mL of the washing solution was added to the test tube containing 9 mL of physiological saline solution and mixed well. The washing solution was then diluted stepwise, and an aliquot (100  $\mu\text{L}$ ) of the diluted solution was placed onto nutrient agar plates and incubated for 24 h at 37  $^{\circ}\text{C}$ . All experiments were performed in triplicate.

### 2.7. Cytotoxicity Assays

The cytotoxicity of the prepared PS@Cu-MOF was then evaluated as described previously [44,47]. More specifically, a fibroblast monolayer was formed on a collagen type I coated glass slide at a density of  $3 \times 10^4$  cells $\cdot\text{cm}^{-1}$  and incubated for 3 h. Non-adhered cells were then rinsed with Dulbecco's Modified Eagle Medium (DMEM supplemented with 10% FBS, 200 IU $\cdot\text{mL}^{-1}$  penicillin, and 200  $\mu\text{g}\cdot\text{mL}^{-1}$  streptomycin), transferred to a 12-well plate, and cultured in the cell culture medium at 37  $^{\circ}\text{C}$  in a humidified incubator containing 5%  $\text{CO}_2$ . The following day, the prepared PS@Cu-MOF (100  $\mu\text{g}\cdot\text{mL}^{-1}$  Cu-MOF-embedded PS, 1.5 cm diameter) was carefully placed on the cell monolayer and incubated for either 1 or 3 d. Thereafter, the cells were stained using a live/dead double-staining protocol [48]. The stained cells were imaged by fluorescence microscopy, and the cell viability was quantified by calculating the percentage of live cells among the total cells. In addition, the cytotoxicity of the extract of PS@Cu-MOF was also evaluated by measuring the cell viability in the presence of the extract solution [49]. For this purpose, PS@Cu-MOF was incubated with the cell culture medium (3  $\text{cm}^2$   $\text{mL}^{-1}$ ) for 24 h to obtain the extract solution, and the cells were seeded in a 24-well plate at a density of  $5 \times 10^4$  cells per well. After incubating at 37  $^{\circ}\text{C}$  for 24 h, the culture medium was replaced in each well using the DMEM medium containing the extract solution (200  $\mu\text{L}$ ). After incubating for 24 h, the DMEM-containing extract solution was replaced with a fresh medium (200  $\mu\text{L}$ ). Subsequently, an aliquot (20  $\mu\text{L}$ ) of the MTS cell proliferation assay kit (Abcam, Cambridge, MA, USA) was added to each well, and incubation was carried out for an additional 4 h. Finally, the colorimetric absorbance of the produced formazan was measured at 490 nm using a microplate reader. The cell viability was calculated using the following equation:

$$\text{cell viability (\%)} = \left( \frac{\text{OD}_{\text{sample}} - \text{OD}_{\text{blank}}}{\text{OD}_{\text{control}} - \text{OD}_{\text{blank}}} \right) \times 100 \quad (2)$$


where  $\text{OD}_{\text{sample}}$  represents the absorbance of the wells containing the extract solution,  $\text{OD}_{\text{control}}$  represents the absorbance of the wells containing only the culture medium, and  $\text{OD}_{\text{blank}}$  represents the absorbance of the wells that contained no cells. The cytotoxicity of PS was also determined using the above method.

## 3. Results and Discussion

### 3.1. Preparation of the Cu-MOF-Embedded PS (PS@Cu-MOF)

As described in Figure 1a, the Cu-MOF was synthesized by a hydrothermal reaction between Glu, bpa, and  $\text{CuNO}_3\cdot 3\text{H}_2\text{O}$  [45]. Its bulk structure was confirmed by PXRD measurements and FT-IR spectroscopy. As illustrated in Figure S1, the main crystalline peaks of Cu-MOF appeared at  $2\theta = 6.8, 13.5, \text{ and } 14.9^{\circ}$ , which corresponded to the (200), (400), and (420) crystal planes, respectively, and are consistent with previous reported literature [46]. The Cu-MOF sample also showed peaks attributed to C-H stretching in the region between 650 and 900  $\text{cm}^{-1}$ , while the peaks at 1602 and 1412  $\text{cm}^{-1}$  were attributed to bidentate inter cluster bridges and to the stretching bands of  $\nu(\text{C-O})$ , respectively (Figure S2) [48]. It was also determined that the crystal structure of Cu-MOF contained dinuclear  $\text{Cu}_2$  units bridged by Glu ligands that formed 2D sheets connected by bpa ligands to give a 3D framework (Figure S3). We prepared PS@Cu-MOF via the facile hydrosilylation reaction of PS-vinyl and Cu-MOF with PS-H in the presence of a Pt catalyst and  $\text{TiO}_2$  additive for 24 h at 25  $^{\circ}\text{C}$  (Figure 1b). The proposed curing mechanism of PDMS was initiated by the insertion reaction of PS-H to the Pt catalyst, followed by PS-vinyl to the Pt-complex via a releasing ligand, elimination of PS by a Si-C coupling reaction, and re-coordination of the released ligand to the Pt catalyst as the final step (Figure 1c). Control

PS was prepared by the same manner without the incorporation of Cu-MOF [50,51]. As shown in Figure 1d, both PS and the PS@Cu-MOF were successfully prepared as thin films, and Cu-MOF was successfully incorporated into the PS during the hydrosilylation process.




**Figure 1.** (a) Schematic illustration of the synthesis of Cu-MOF. (b) Hydrosilylation of vinyl-terminated PS and hydrogen-terminated PS with Cu-MOF in the presence of a Pt catalyst. (c) Curing mechanism for the hydrosilylation of PS-vinyl and PS-H containing a Pt catalyst. (d) Photographic images of PS and the PS@Cu-MOF. Scale bar: 0.5 cm.

### 3.2. Characterization of the PS@Cu-MOF

The PXRD patterns of PS, Cu-MOF, and PS@Cu-MOF were analyzed to study the nature of crystallinity of each sample. As illustrated in Figure 2a, two broad intense peaks were observed for PS and PS@Cu-MOF, namely a large peak at  $\sim 12.8^\circ$  and a smaller and broader peak at  $22.6^\circ$ , which were assigned to PS and  $\text{TiO}_2$ , respectively, and corresponded with the previous reported literature [52,53]. Furthermore, PS@Cu-MOF exhibited additional crystalline peaks at  $2\theta = 6.8^\circ$ , pertaining to the crystal planes of Cu-MOF (Figure S1). These results confirm the successful embedding of Cu-MOF in the PS networks. Figure 2b shows typical DSC scans performed at identical heating rates for the PS and PS@Cu-MOF

samples. The glass transition temperatures ( $T_g$ ) of both samples were observed similarly below  $-100\text{ }^\circ\text{C}$ , indicating that the  $T_g$  was not affected by the embedding of Cu-MOF on the PS. In addition, a single melting peak at around  $-40\text{ }^\circ\text{C}$  was observed for the two PS-based species, which is common in cross-linked PS materials owing to the inability of the crosslinks to crystallize [54]. The thermogravimetric analyses of PS and PS@Cu-MOF were also carried out, wherein a single weight loss step (43.0 and 42.3%, respectively, at  $511\text{ }^\circ\text{C}$ ) and similar thermal degradation paths were observed in an inert atmosphere (Figure 2c). This decomposition tendency suggests that the two PS networks are not significantly different from one another, i.e., the incorporation of Cu-MOF does not significantly affect the PS network. FT-IR spectral analysis was also performed. Figure S4 shows four strong and sharp peaks: the asymmetric C-H bending at  $2961\text{ cm}^{-1}$ , the symmetric C-H bending at  $1258\text{ cm}^{-1}$ , the asymmetric Si-O-Si stretching at  $1009\text{ cm}^{-1}$ , and Si-C stretching at  $785\text{ cm}^{-1}$  in both PS@Cu-MOF and PS samples, whereas the Cu-MOF related peak did not occur from PS@Cu-MOF due to their low concentration in PS [55].



**Figure 2.** Characterization of PS and PS@Cu-MOF; (a) PXRD patterns, (b) DSC scans, and (c) TGA profiles.

Moreover, analysis by SEM-EDS was carried out to obtain the morphologies and chemical compositions of the control PS and the PS@Cu-MOF. Figure 3 shows representative SEM images in addition to the corresponding mapping results for both species. More specifically, Si, Ti, and Pt were evenly spread throughout both networks (C and O were skipped), and the additional element of Cu was also found in the EDS spectrum of PS@Cu-MOF. These data confirm the embedding of Cu-MOF on PS following the above-described hydrosilylation reaction and agree with aforementioned PXRD patterns.


### 3.3. Mechanical Properties of PS@Cu-MOF

The storage moduli of PS and PS@Cu-MOF were measured to analyze their mechanical properties. As shown in Figure 4a, PS@Cu-MOF exhibited stable rheological properties ( $50.6 \pm 0.2\text{ kPa}$ ) and a similar modulus to PS ( $49.8 \pm 0.3\text{ kPa}$ ). Figure 4b shows the swelling behaviors of PS@Cu-MOF and PS, where low swelling ratios ( $1.01 \pm 0.01$  and  $1.03 \pm 0.03$ ) are apparently due to the inherent hydrophobicity of PS. These results therefore indicate that PS@Cu-MOF has a polymeric network structure very similar to that of the control PS, and that the small amount of Cu-MOFs does not significantly affect the mechanical strength.


### 3.4. Antibacterial Activity Tests

The antibacterial activity of Cu-MOF has been previously reported against various strains of bacteria, including Gram-negative and Gram-positive bacteria, with Cu-MOF exhibiting excellent bactericidal properties [45]. We therefore decided to embed an antibacterial Cu-MOF to the PS to develop a new medicinal sheet, and we tested the bactericidal effects of both PS and the prepared PS@Cu-MOF against *E. coli*, *S. aureus*, and MRSA at  $100\text{ }\mu\text{g}\cdot\text{mL}^{-1}$  to evaluate the material potential for medicinal application. As shown in Figure 5 and Table 1, the bactericidal effect of the control PS increased in the following order: MRSA (20.0%) < *S. aureus* (31.8%) < *E. coli* (44.8%); this can be attributed to the antibacterial properties of the Pt catalyst and the  $\text{TiO}_2$  additive [56,57]. Upon embedding


the Cu-MOFs in PS, the bactericidal effect was significantly increased as follows: MRSA (81.6%) < *S. aureus* (87.7%) < *E. coli* (88.8%). These results demonstrate that PS@Cu-MOF exhibits an excellent bactericidal effect on both Gram-negative bacteria (*E. coli*) and Gram-positive bacteria (*S. aureus*, MRSA) and shows better antibacterial activity than previously reported antibacterial polysiloxanes [58]. Graphene oxide-catechol composite (GO-DMA) was modified onto the surface of PDMS. The antibacterial activity of GO-DMA-PDMS was evaluated against *E. coli* and *S. aureus*. Antibacterial GO-DMA-PDMS killed *S. aureus* (42%) and *E. coli* (37%). Based on this result, Cu-MOF embedded PS is more bioactive than the previously published antibacterial surface-coated PDMS.



**Figure 3.** SEM images of PS and PS@Cu-MOF with the accompanying EDS spectra and corresponding elemental maps. Scale bar: 50  $\mu\text{m}$ .



**Figure 4.** Physical properties of PS and PS@Cu-MOF. (a) Storage modulus and (b) swelling ratio of PS and PS@Cu-MOF (n = 4).



**Figure 5.** (a) Representative images of bacteria grown on PS and PS@Cu-MOF after incubation for 24 h: Top (blank), middle (PS), and bottom (PS@Cu-MOF); left to right: *E. coli*, *S. aureus*, and MRSA. (b) The antibacterial efficiency of PS and PS@Cu-MOF towards *E. coli*, *S. aureus*, and MRSA (means  $\pm$  standard deviation with  $n = 3$ ; \*\*:  $p < 0.01$ ).

**Table 1.** Antibacterial activity of the MOF-embedded PS against various bacteria.


| Test Items       |           | Test Results <sup>a,b</sup>         |   |                                |
|------------------|-----------|-------------------------------------|---|--------------------------------|
|                  |           | Early Conc. (cfu·mL <sup>-1</sup> ) | After 24 h, Conc. (cfu·mL <sup>-1</sup> ) | Reduction Rate of Bacteria (%) |
| <i>E. coli</i>   | blank     | $3.4 \times 10^5$                   | $9.8 \times 10^6$                         | -                              |
|                  | PS        | $3.4 \times 10^5$                   | $5.4 \times 10^6$                         | 44.8                           |
|                  | blank     | $1.2 \times 10^5$                   | $3.8 \times 10^6$                         | -                              |
|                  | PS@Cu-MOF | $1.2 \times 10^5$                   | $4.3 \times 10^5$                         | 88.6                           |
| <i>S. aureus</i> | blank     | $3.6 \times 10^5$                   | $9.1 \times 10^6$                         | -                              |
|                  | PS        | $3.6 \times 10^5$                   | $6.2 \times 10^6$                         | 31.8                           |
|                  | blank     | $1.6 \times 10^5$                   | $2.2 \times 10^6$                         | -                              |
|                  | PS@Cu-MOF | $1.6 \times 10^5$                   | $2.7 \times 10^5$                         | 87.7                           |
| MRSA             | blank     | $3.6 \times 10^5$                   | $9.0 \times 10^6$                         | -                              |
|                  | PS        | $3.6 \times 10^5$                   | $7.2 \times 10^6$                         | 20.0                           |
|                  | blank     | $3.0 \times 10^5$                   | $9.8 \times 10^5$                         | -                              |
|                  | PS@Cu-MOF | $3.0 \times 10^5$                   | $1.8 \times 10^5$                         | 81.6                           |

<sup>a</sup> test method: KCL-FIR1003: 2018. <sup>b</sup> test environment:  $(37.0 \pm 0.2)^\circ\text{C}$ , Conc.  $100 \mu\text{g}\cdot\text{mL}^{-1}$ .

### 3.5. Ion Release Tests

Degradation tests were then performed on the PS@Cu-MOF in 0.9% PBS at  $25^\circ\text{C}$  for 6, 12, 24, and 48 h, and the quantity of copper metal ions released from Cu-MOF was measured by ICP-MS. As shown in Figure 6, the concentration of metal ions released from PS@Cu-MOF increased to  $0.112 \mu\text{g}\cdot\text{mL}^{-1}$  during the initial 6 h, and then decreased until the 24 h point ( $0.065 \mu\text{g}\cdot\text{mL}^{-1}$ ), after which it slightly increased again up to 48 h ( $0.067 \mu\text{g}\cdot\text{mL}^{-1}$ ). The average concentration of Cu(II) ions released from PS@Cu-MOF after 24 h, i.e.,  $0.089 \mu\text{g}\cdot\text{mL}^{-1}$ , was lower than in the case of the Cu-MOF alone [37,38]. These results indicate that PS@Cu-MOF maintains its robust framework on the polymer network while also exhibiting excellent bactericidal properties against the various bacterial strains without the participation of released metal ions.






**Figure 6.** Concentration of Cu(II) ions released from PS@Cu-MOF (1 mg) in 0.9% PBS (1 mL).

### 3.6. Cytotoxicity of PS@Cu-MOF

Finally, we studied the cell biocompatibility of PS@Cu-MOF based on a direct contact method [47]. To verify the toxicity of the PS itself, PS (i.e., without the Cu-MOF) was prepared using the same method employed for its use as a positive control. Furthermore, as an additional positive control (blank), a mouse embryonic fibroblast (MEF) monolayer without any PS or PS@MOF contact was prepared. As a negative control, an MEF monolayer contact with a 10% EtOH solution was used. The viability of the MEF monolayer was monitored using live/dead staining as well as an MTS assay. As shown in the fluorescence microscopy images (Figure 7a), the cell viabilities for the blank, PS, and PS@Cu-MOF ( $100 \mu\text{g}\cdot\text{mL}^{-1}$ ) samples exceeded 98% for 1 d after culture, whereas in the case of the MEF monolayer, the majority of cells died upon exposure to EtOH. It was found that the cells gradually adhered, spread, and flattened on the surface after seeding, prior to forming a confluent-like layer that survived for 3 d; this was not observed in the case of the EtOH group. These results indicate that neither the MOF-embedded PS nor the PS alone were toxic to the cells. Further quantification was carried out using an MTS assay (Figure 7b), wherein extracted cell culture medium solutions from PS and PS@Cu-MOF were serially diluted. For example, 100% refers to the original extraction medium, and 25% indicates a four times dilution from the original extraction medium. Following formation of the MEF monolayer, the culture medium was changed to the desired concentration medium containing the extract solution, and cultured. The obtained MTS results demonstrated the good cytocompatibilities of PS and PS@Cu-MOF, as the MEF viability was >93% in all cases, whereas the majority of MEFs died upon exposure to EtOH, thereby confirming the low cytotoxicity of the PS and PS@Cu-MOF extracts.



**Figure 7.** (a) Staining images of the live/dead MEFs after contact with PS only or PS@Cu-MOF for 1 or 3 d. Cells cultured without any PS contact were used as a positive control. As a negative control, cells exposed to EtOH were used. (b) In vitro cytotoxicity of the extract solution of PS and PS@Cu-MOF to MEFs (n = 4); means  $\pm$  standard deviation with n = 4; NS: not significant; \*\*\*  $p < 0.001$ . Scale bar: 200  $\mu\text{m}$ .

#### 4. Conclusions

In this work, we successfully modified the surfaces of polysiloxanes (PSs) with copper-containing metal–organic frameworks (Cu-MOFs) via a hydrosilylation reaction. Modification was performed at room temperature without the requirement for any special equipment. The bactericidal activities of the Cu-MOF-embedded PS (i.e., PS@Cu-MOF) and the control PS were tested against three strains of bacteria, namely *E. coli*, *S. aureus*, and MRSA. Importantly, PS@Cu-MOF exhibited superior antibacterial properties toward the tested bacteria than the control PS, in addition to a low cytotoxicity toward mouse embryonic fibroblasts at a concentration of 100  $\mu\text{g}\cdot\text{mL}^{-1}$ . In addition, Cu(II) ion release tests confirmed the excellent stability of PS@Cu-MOF in phosphate-buffered saline. Furthermore, the physical and thermal properties of PS@Cu-MOF, such as its phase transition, swelling ratio, and thermogravimetric profile, were comparable to those of the control PS. Moreover, its low cytotoxicity and high bactericidal activity indicate the potential of PS@Cu-MOF as a promising new candidate for medicinal applications, such as in implants, the treatment of skin disease, wound healing, and drug delivery. In summary, we attempted to efficiently improve the antibacterial activity of PS@Cu-MOF utilizing the synergy effect by blending with other additives, and we drove the development of another new bioactive PS. We believe that our findings could be useful for manufacturing a silicone-based implanting device with antibacterial activity in a straightforward and economically competitive way. However, further work, including in vivo experiments, is required to promote the future use of Cu-MOF-embedded PS as a new generation of powerful antibacterial agents and devices with wide-ranging applications.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/2079-4991/11/3/719/s1>, Figure S1: PXRD pattern of Cu-MOF, Figure S2: FT-IR spectrum of Cu-MOF, Figure S3: Crystal structure of Cu-MOF, Figure S4: FT-IR spectrum of PS and PS@Cu-MOF.

**Author Contributions:** Conceptualization, K.G. and D.N.L.; methodology, K.G., Y.K., H.C., S.-H.Y. and S.-J.K.; validation, H.C.; formal analysis, K.G., Y.K., S.L.; Investigation, S.-H.Y.; data curation, K.G., Y.K., H.C., S.L., S.-H.Y. and S.-J.K.; writing—original draft preparation, K.G.; writing—review and editing, Y.K., S.L. and D.N.L.; supervision, D.N.L.; funding acquisition, K.G., Y.K., S.L. and D.N.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Basic Science Research Program of the National Research Foundation of Korea (2017R1A6A3A11030955, 2018R1D1A1B07045327, and 2021R1A2C1004285) and by Kwangwoon University in the year 2020. This work was also supported by the Center for Women in Science, an Engineering and Technology (WISET) Grant funded by the Ministry of Science and ICT (MSIT) under the Program for Returners into R&D.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Data is available on the request from the corresponding author.

**Acknowledgments:** The authors would also like to thank the Korean Basic Science Institute in Seoul for carrying out the ICP-MS analysis.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Chen, C.Z.S.; Cooper, S.L. Recent advances in antimicrobial dendrimers. *Adv. Mater.* **2000**, *12*, 843–846. [[CrossRef](#)]
2. Gabriel, G.J.; Som, A.; Madkour, A.E.; Eren, T.; Tew, G.N. Infectious disease: Connecting innate immunity to biocidal polymers. *Mater. Sci. Eng. R. Rep.* **2007**, *57*, 28–64. [[CrossRef](#)] [[PubMed](#)]
3. Hadesfandiari, N.; Yu, K.; Mei, Y.; Kizhakkedathu, J.N. Polymer brush-based approaches for the development of infection-resistant surfaces. *J. Mater. Chem. B* **2014**, *2*, 4946–4978. [[CrossRef](#)]
4. Zhao, D.; Zhu, T.; Li, J.; Cui, L.; Zhang, Z.; Zhuang, X.; Ding, J. Poly(lactic-co-glycolic acid)-based composite bone-substitute materials. *Bioact. Mater.* **2021**, *6*, 346–360. [[CrossRef](#)]
5. Zhu, T.; Cui, Y.; Zhang, M.; Zhao, D.; Liu, G.; Ding, J. Engineered three-dimensional scaffolds for enhanced bone regeneration in osteonecrosis. *Bioact. Mater.* **2020**, *5*, 584–601. [[CrossRef](#)]
6. Li, S.; Dong, S.; Xu, W.; Tu, S.; Yan, L.; Zhao, C.; Ding, J.; Chen, X. Antibacterial hydrogels. *Adv. Sci.* **2018**, *5*, 1700527. [[CrossRef](#)] [[PubMed](#)]
7. Timofeeva, L.; Kleshcheva, K. Antimicrobial polymers: Mechanism of action, factors of activity, and applications. *Appl. Microbiol. Biotechnol.* **2011**, *89*, 475–492. [[CrossRef](#)] [[PubMed](#)]
8. Rupa, S.; Dutta, B.; Singh, S.P.; Rathor, A. Research article case report: Silicone implant in augmentation of saddle nose. *Int. J. Recent Sci. Res.* **2013**, *4*, 1661–1662.
9. Elist, J.J.; Shirvanian, V.; Lemperle, G. Surgical treatment of penile deformity due to curvature using a subcutaneous soft silicone implant: Case report. *Open J. Urol.* **2014**, *4*, 91–97. [[CrossRef](#)]
10. Beigbeder, A.; Labruyère, C.; Viville, P.; Pettitt, M.E.; Callow, J.A. Surface and fouling-release properties of silicone/organomodified montmorillonite coatings. *J. Adhes. Sci. Tech.* **2011**, *25*, 1689–1700. [[CrossRef](#)]
11. Mark, J.E. Some interesting things about polysiloxanes. *Acc. Chem. Res.* **2004**, *37*, 946–953. [[CrossRef](#)]
12. Hogg, A.; Aellen, T.; Uhl, S.; Graf, B.; Keppner, H.; Tardy, Y.; Burger, J. Ultra-thin layer packaging for implantable electronic devices. *J. Micromech. Microeng.* **2013**, *23*, 075001. [[CrossRef](#)]
13. Teo, A.J.T.; Mishra, A.; Park, I.; Kim, Y.-J.; Park, W.-T.; Yoon, Y.-J. Polymeric biomaterials for medical implants and devices. *ACS Biomater. Sci. Eng.* **2016**, *2*, 454–472. [[CrossRef](#)]
14. Hassler, C.; von Metzzen, R.P.; Ruther, P.; Stieglitz, T. Characterization of parylene C as an encapsulation material for implanted neural prostheses. *J. Biomed. Mater. Res. Part B Appl. Biomater.* **2010**, *93*, 266–274. [[CrossRef](#)]
15. Van Zele, D.; Heymans, O. Breast implants. A review. *Acta Chir. Belg.* **2004**, *104*, 158–164. [[CrossRef](#)]
16. Lo, R.; Li, P.Y.; Saati, S.; Agrawal, R.; Humayun, M.S.; Meng, E. A refillable microfabricated drug delivery device for treatment of ocular diseases. *Lab Chip* **2008**, *8*, 1027–1030. [[CrossRef](#)]
17. Lo, R.; Li, P.Y.; Saati, S.; Agrawal, R.N.; Humayun, M.S.; Meng, E. A passive MEMS drug delivery pump for treatment of ocular diseases. *Biomed. Microdevices* **2009**, *11*, 959–970. [[CrossRef](#)]
18. Yilgör, E.; Yilgör, I. Silicone containing copolymers: Synthesis, properties and applications. *Prog. Polym. Sci.* **2014**, *39*, 1165–1195. [[CrossRef](#)]

19. Rahimi, A.; Mashak, A. Review on rubbers in medicine: Natural, silicone and polyurethane rubbers. *Plast. Rubber Compos.* **2013**, *42*, 223–230. [[CrossRef](#)]
20. Nikolova, M.P.; Chavali, M.S. Recent advances in biomaterials for 3D scaffolds: A review. *Bioact. Mater.* **2019**, *4*, 271–292. [[CrossRef](#)] [[PubMed](#)]
21. Qin, Y.; Howlader, M.M.R.; Deen, M.J.; Haddara, Y.M.; Selvaganapathy, P.R. Polymer integration for packaging of implantable sensors. *Sens. Actuat. B Chem.* **2014**, *202*, 758–778. [[CrossRef](#)]
22. Kugel, A.; Chisholm, B.; Ebert, S.; Jepperson, M.; Jarabek, L.; Staflieni, S. Antimicrobial polysiloxane polymers and coatings containing pendant. *Polym. Chem.* **2010**, *1*, 442–452. [[CrossRef](#)]
23. Islas, M.S.; Medina, J.J.M.; López Tévez, L.L.; Rojo, T.; Lezama, L.; Merino, M.G.; Calleros, L.; Cortes, M.A.; Puyol, R.M.; Echeverría, G.A.; et al. Antitumoral, antihypertensive, antimicrobial, and antioxidant effects of an octanuclear copper (II)-telmisartan complex with an hydrophobic nanometer hole. *Inorg. Chem.* **2014**, *53*, 5724–5737. [[CrossRef](#)] [[PubMed](#)]
24. Jaros, S.W.; Guedes da Silva, M.F.C.; Król, J.; Oliveira, M.C.; Smoleński, P.; Pombeiro, A.J.L.; Kirillov, A.M. Bioactive silver–organic networks assembled from 1,3,5-triaza-7-phosphaadamantane and flexible cyclohexanecarboxylate blocks. *Inorg. Chem.* **2016**, *55*, 1486–1496. [[CrossRef](#)]
25. Wang, L.; Yang, W.; Zhu, W.; Guan, X.; Xie, Z.; Sun, Z.-M. A nanosized {Ag@Ag<sub>12</sub>} “molecular windmill” templated by polyoxometalates anions. *Inorg. Chem.* **2014**, *53*, 11584–11588. [[CrossRef](#)] [[PubMed](#)]
26. Chojnowski, J.; Fortuniak, W.; Rościszewski, P.; Werel, W.; Łukasiak, J.; Kamysz, W.; Hałasa, R. Polysilsesquioxanes and oligosilsesquioxanes substituted by alkylammonium salts as antibacterial biocides. *J. Inorg. Organomet. Polym. Mater.* **2006**, *16*, 219–230. [[CrossRef](#)]
27. Mansouri, J.; Truong, V.K.; MacLaughlin, S.; Mainwaring, D.E.; Moad, G.; Dagley, I.J.; Ivanova, E.P.; Crawford, R.J.; Chen, V. Polymerization-Induced Phase Segregation and Self-Assembly of Siloxane Additives to Provide Thermoset Coatings with a Defined Surface Topology and Biocidal and Self-Cleaning Properties. *Nanomaterials* **2019**, *9*, 1610. [[CrossRef](#)] [[PubMed](#)]
28. Mizerska, U.; Fortuniak, W.; Chojnowski, J.; Hałasa, R.; Konopacka, A.; Werel, W. Polysiloxane cationic biocides with imidazolium salt (ImS) groups, synthesis and antibacterial properties. *Eur. Polym. J.* **2009**, *45*, 779–787. [[CrossRef](#)]
29. Mizerska, U.; Fortuniak, W.; Chojnowski, J.; Turecka, K.; Konopacka, A.; Werel, W. Antimicrobial siloxane statistical and graft copolymers substituted with t-butylamine and t-butylammonium biocidal functions. *J. Inorg. Organomet. Polym. Mater.* **2010**, *20*, 554–563. [[CrossRef](#)]
30. Rozga-Wijas, K.; Mizerska, U.; Fortuniak, W.; Chojnowski, J.; Hałasa, R.; Werel, W. Quaternary ammonium salts (QAS) modified polysiloxane biocide supported on silica materials. *J. Inorg. Organomet. Polym. Mater.* **2007**, *17*, 605–613. [[CrossRef](#)]
31. Chisholm, B.J.; Majumdar, P. Antimicrobial Polysiloxane Materials Containing Metal Species. U.S. Patent 8,709,394 B2, 29 April 2014.
32. Yilgor, E.; Nugay, I.I.; Bakan, M.; Yilgor, I. Antibacterial silicone-urea/organoclay nanocomposites. *Silicon* **2009**, *1*, 183–190. [[CrossRef](#)]
33. Prasse, M.; Christofferson, A.J.; Elbourne, A.; Cheeseman, S.; Shi, Y.; Rolland, M.; Cozzolino, D.; Chapman, J.; McConville, C.F.; Crawford, R.J.; et al. Conformationally tuned antibacterial oligomers target the peptidoglycan of Gram-positive bacteria. *J. Colloid Interface Sci.* **2020**, *580*, 850–862.
34. Liu, Q.; Ning, D.; Li, W.-J.; Du, X.-M.; Wang, Q.; Li, Y.; Ruan, W.-J. A point-of-care diagnostics logic detector based on glucose oxidase immobilized lanthanide functionalized metal–Organic frameworks. *Analyst* **2019**, *114*, 1916–1922. [[CrossRef](#)]
35. Sava Gallis, D.F.; Butler, K.S.; Agola, J.O.; Pearce, C.J.; McBride, A.A. Antibacterial countermeasures via metal–organic framework-supported sustained therapeutic release. *ACS Appl. Mater. Interfaces* **2019**, *11*, 7782–7791. [[CrossRef](#)] [[PubMed](#)]
36. Lu, X.; Ye, J.; Zhang, D.; Xie, R.; Bogale, R.F.; Sun, Y.; Zhao, L.; Zhao, Q.; Ning, G. Silver carboxylate metal-organic frameworks with highly antibacterial activity and biocompatibility. *J. Inorg. Biochem.* **2014**, *138*, 114–121. [[CrossRef](#)]
37. Wang, S.; Yan, F.; Ren, P.; Li, Y.; Wu, Q.; Fang, X.; Chen, F.; Wang, C. Incorporation of metal-organic frameworks into electrospun chitosan/poly (vinyl alcohol) nanofibrous membrane with enhanced antibacterial activity for wound dressing application. *Int. J. Biol. Macromol.* **2020**, *158*, 9–17. [[CrossRef](#)]
38. Rubin, H.N.; Neufeld, B.H.; Reynolds, M.M. Surface-anchored metal–Organic framework–Cotton material for tunable antibacterial copper delivery. *ACS Appl. Mater. Interfaces* **2018**, *10*, 15189–15199. [[CrossRef](#)]
39. Sharma, V.K.; Yngard, R.A.; Lin, Y. Silver nanoparticles: Green synthesis and their antimicrobial activities. *Adv. Colloid Interface Sci.* **2009**, *145*, 83–96. [[CrossRef](#)]
40. Li, H.; Duan, X.; Liu, G.; Liu, X. Photochemical synthesis and characterization of Ag/TiO<sub>2</sub> nanotube composites. *J. Mater. Sci.* **2008**, *43*, 1669–1676. [[CrossRef](#)]
41. Zeng, H.; Zhao, C.; Qiu, J.; Yang, Y.; Chen, G. Preparation and optical properties of silver nanoparticles induced by a femtosecond laser irradiation. *J. Cryst. Growth* **2007**, *300*, 519–522. [[CrossRef](#)]
42. Chen, Y.; Han, Q.; Wang, Y.; Zhang, Q.; Qiao, X. Synthesis of pyridinium polysiloxane for antibacterial coating in supercritical carbon dioxide. *J. Appl. Polym. Sci.* **2015**, *132*, 41723. [[CrossRef](#)]
43. Jońca, J.; Tukaj, C.; Werel, W.; Mizerska, U.; Fortuniak, W.; Chojnowski, J. Bacterial membranes are the target for antimicrobial polysiloxane-methacrylate copolymer. *J. Mater. Sci. Mater. Med.* **2016**, *27*, 55. [[CrossRef](#)] [[PubMed](#)]
44. Gwon, K.; Han, I.; Lee, S.; Kim, Y.; Lee, D.N. Novel metal–Organic framework-based photocrosslinked hydrogel system for efficient antibacterial applications. *ACS Appl. Mater. Interface* **2020**, *12*, 20234–20242. [[CrossRef](#)]

45. Jo, J.H.; Kim, H.-C.; Huh, S.; Kim, Y.; Lee, D.N. Antibacterial activities of Cu-MOFs containing glutarates and bipyridyl ligands. *Dalton Trans.* **2019**, *48*, 8084–8093. [[CrossRef](#)]
46. Hwang, I.H.; Bae, J.M.; Kim, W.-S.; Jo, Y.D.; Kim, C.; Kim, Y.; Kim, S.-J.; Huh, S. Bifunctional 3D Cu-MOFs containing glutarates and bipyridyl ligands: Selective CO<sub>2</sub> sorption and heterogeneous catalysis. *Dalton Trans.* **2012**, *41*, 12759. [[CrossRef](#)]
47. Gwon, K.; Jo, E.-J.; Sahu, A.; Lee, J.Y.; Kim, M.-G.; Tae, G. Improved near infrared-mediated hydrogel formation using diacrylated Pluronic F127-coated upconversion nanoparticles. *Mater. Sci. Eng. C* **2018**, *90*, 77–84. [[CrossRef](#)]
48. Cheng, X.; Liu, J.; Wang, L.; Wang, R.; Liu, Z.; Zhou, R. An enzyme-mediated in situ hydrogel based on polyaspartamide derivatives for localized drug delivery and 3D scaffolds. *RSC Adv.* **2016**, *6*, 101334–101346. [[CrossRef](#)]
49. Siew, W.Y.; Abu Bakar, N.H.H.; Abu Bakar, M. The influence of green synthesis on the formation of various copper benzene-1,3,5-tricarboxylate compounds. *Inorg. Chim. Acta* **2018**, *482*, 53–61. [[CrossRef](#)]
50. Meister, T.K.; Riener, K.; Gigler, P.; Stohrer, J.; Herrmann, W.A.; Kühn, F.E. Platinum catalysis revisited—Unraveling principles of catalytic olefin hydrosilylation. *ACS Catal.* **2016**, *6*, 1274–1284. [[CrossRef](#)]
51. Nakajima, Y.; Shimada, S. Hydrosilylation reaction of olefins: Recent advances and perspectives. *RSC Adv.* **2015**, *5*, 20603–20616. [[CrossRef](#)]
52. Ferreira, P.; Carvalho, Á.; Ruivo Correia, T.; Paiva Antunes, B.; Joaquim Correia, I.; Alves, P. Functionalization of polydimethylsiloxane membranes to be used in the production of voice prostheses. *Sci. Technol. Adv. Mater.* **2013**, *14*, 055006. [[CrossRef](#)] [[PubMed](#)]
53. Al-Taweel, S.S.; Saud, H.R. New route for synthesis of pure anatase TiO<sub>2</sub> nanoparticles via ultrasound-assisted sol-gel method. *J. Chem. Pharm. Res.* **2016**, *8*, 620–626.
54. Fan, J.; Huang, J.; Yan, M.; Gong, Z.; Gao, L.; Chen, Y. Thermoplastic multifunctional polysiloxane-based materials from broad gradient-transition multiphase separation. *J. Mater. Chem. A* **2020**, *8*, 16376–16384. [[CrossRef](#)]
55. González-Rivera, J.; Iglío, R.; Barillaro, G.; Duce, C.; Tinè, M.R. Structural and Thermoanalytical Characterization of 3D Porous PDMS Foam Materials: The Effect of Impurities Derived from a Sugar Templating Process. *Polymers* **2018**, *10*, 616. [[CrossRef](#)] [[PubMed](#)]
56. Staszek, M.; Siegel, J.; Kolářová, K.; Rimpelová, S.; Švorčík, V. Formation and antibacterial action of Pt and Pd nanoparticles sputtered into liquid. *Micro Nano Lett.* **2014**, *9*, 778–781. [[CrossRef](#)]
57. Wanag, A.; Rokicka, P.; Kusiak-Nejman, E.; Kapica-Kozar, J.; Wrobel, R.J.; Markowska-Szczupak, A.; Morawski, A.W. Antibacterial properties of TiO<sub>2</sub> modified with reduced graphene oxide. *Ecotoxicol. Environ. Saf.* **2018**, *147*, 788–793. [[CrossRef](#)]
58. Tu, Q.; Zhang, Q.; Wang, Y.; Jiao, J.; Peng, T.; Wang, J. Antibacterial properties of poly(dimethylsiloxane) surfaces modified with graphene oxide-catechol composite. *Prog. Org. Coat.* **2019**, *127*, 247–253. [[CrossRef](#)]